Problems in daily motor performances in Parkinson's disease: the continuous dopaminergic stimulation.
Fluctuations in motor performances are the major problem in the longterm management of Parkinson's disease. In this study the clinical effects of L-dopa intravenous infusion were evaluated in 18 parkinsonian patients with fluctuations. 14 out of these were given Lisuride intravenous infusion in a following study. Lisuride is a potent dopamine agonist and it is highly soluble in water. The results obtained with L-dopa were very good and we found a close correlation between oral and intravenous dosage. The dosage of L-dopa infusion ranged between 360-1,250 mg for 12 hours. Lisuride proved to be able to give prolonged mobile state in 8 patients out of 14. The other 6 patients showed a different response to the drug. The dosage used ranged between 0.6 and 2.4 mg per day. No severe side-effects were observed during both studies except for nausea and vomiting occurring during Lisuride infusion.
Stocchi
F
F
Ruggieri
S
S
Brughitta
G
G
Agnoli
A
A
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D002230:Carbidopa / Q000494:pharmacology; D004294:Domperidone / Q000494:pharmacology; D004873:Ergolines / Q000494:pharmacology*; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D007980:Levodopa / Q000008:administration & dosage / Q000494:pharmacology*; D008090:Lisuride / Q000008:administration & dosage / Q000494:pharmacology*; D008297:Male; D008875:Middle Aged; D009069:Movement Disorders / Q000503:physiopathology*; D010300:Parkinson Disease / Q000503:physiopathology*
D004873:Ergolines; D007980:Levodopa; D004294:Domperidone; D008090:Lisuride; D002230:Carbidopa